ECOG E1910 (also called E1910) was a pivotal Phase III randomized clinical trial conducted by the ECOG‑ACRIN Cancer Research Group. It evaluated whether adding blinatumomab (a bispecific T‑cell engager targeting CD19) to standard consolidation chemotherapy improves outcomes for adults (ages 30–70) with newly diagnosed, Philadelphia chromosome–negative B‑cell precursor acute lymphoblastic leukemia (B‑ALL) who were in MRD‑negative remission following induction
ECOG1910 Regimen Components
1. Induction Chemotherapy (to achieve CR ± MRD-negativity)
- Vincristine (Vinca alkaloid, IV)
- Dexamethasone (corticosteroid, oral/IV)
- Daunorubicin (anthracycline, IV)
- PEG-asparaginase (enzyme, IM/IV)
- Intrathecal methotrexate ± cytarabine (CNS prophylaxis)
2. Randomization Phase (after induction, in CR and MRD assessed)
- Control Arm (Chemotherapy only):
- Multi-agent consolidation & maintenance chemotherapy (including cytarabine, cyclophosphamide, 6-mercaptopurine, methotrexate, vincristine, dexamethasone).
- Standard intrathecal prophylaxis continued.
- Experimental Arm (Chemo + Blinatumomab):
- Blinatumomab (anti-CD19 BiTE, continuous IV infusion, 28-day cycles).
- Given in two cycles intercalated during consolidation, then patients continued with standard chemotherapy and maintenance.
3. Maintenance Therapy
- 6-Mercaptopurine (oral)
- Methotrexate (oral or IV weekly)
- Vincristine (monthly IV)
- Prednisone pulses
Duration: typically 2 years from start of maintenance (standard for adult ALL).
Key Point: The trial compared consolidation chemo alone vs consolidation chemo + blinatumomab, on top of an induction → consolidation → maintenance chemotherapy backbone.